C
ongenital heart disease (CHD), defined as an abnormality in gross cardiac anatomy occurring in utero, represents the most prevalent group of congenital anomalies. 1, 2 These heterogeneous disorders may vary from single atrial or ventricular defects to complex malformations, such as the complete absence of a cardiac chamber or transposition of major blood vessels. 1 Although mortality rates may be significantly different across types of CHD, overall prognosis is thought to have substantially improved in recent years. 2, 3 Surgery constitutes the gold standard for the treatment of CHD, with single-stage or staged procedures currently being indicated in different types of congenital cardiac anomalies. For instance, patients with hypoplastic left heart syndrome (HLHS) typically undergo a series of palliative procedures; stage I Norwood palliative operation (at birth), stage II palliative bidirectional cavopulmonary connection (4-6 months), and stage III palliative total cavopulmonary (Fontan) operation (18-48 months) . 4 The timing of the operation mainly depends on the severity of the defect, with certain patients needing a surgical intervention within days or weeks from birth and others undergoing surgical correction in early childhood or even adulthood. 1 Patients with Tetralogy of Fallot usually undergo surgical repair once at 3 to 6 months of age; the aim is to relieve the blood flow obstruction from the right ventricle to the pulmonary artery and close the ventricular septum defect, but patients may additionally need pulmonary valve replacement during the course of their lives. 5 Despite significant progress in fetal and neonatal care, the management of patients with CHD may still be problematic in certain scenarios, such as early obstruction of stents, unmatched growth of prosthetic implants with the infant's heart, and ventricular dysfunction after staged palliative surgery. [6] [7] [8] Ultimately, many patients with CHD will develop heart failure requiring heart transplantation. Even after heart transplantation, 5-year survival seems to be ≈60% for patients with CHD who have undergone a Fontan operation. 9 In addition, given the technical challenges and morbidity of CHD repairs and heart transplants, efforts have been made to find alternative treatment options for patients with congenital cardiac defects. [10] [11] [12] Because of their regenerative potential, stem cells have emerged as a potential treatment option for a range of diseases in cardiovascular medicine, including CHD. This approach was initially explored for treating adult patients with myocardial infarction and heart failure (HF). 13 In recent years, numerous preclinical and clinical studies have assessed the feasibility and efficacy of stem cell therapy in both ischemic and nonischemic cardiomyopathy. 13 Various populations of stem cells have been evaluated, including bone marrow mononuclear cells and mesenchymal and cardiac stem cells, and they seem to exhibit encouraging results in terms of safety and efficacy. [14] [15] [16] [17] [18] A large body of literature evaluating the use of stem cells in adult cardiac disease is currently available, but the evidence on stem cell therapy for CHD is less robust. 19 The present systematic review aims to summarize and critically assess all available data on the implementation of stem cell therapy in CHD, highlighting their promising therapeutic potential as well as their current limitations and shortcomings. To provide a comprehensive overview of the field, we analyzed data from published preclinical and clinical studies as well as ongoing clinical trials.
METHODS Protocol Registration, Search Strategy, and Data Sources
A study protocol was agreed a priori and followed by all authors. Complete details including electronic search strategy, objectives, criteria for study selection, eligibility, and data collection were published online and registered with the Research Registry database (registration no. researchregistry2515). 20 The systematic review was conducted in accordance
Clinical Perspective
What Is New?
• The use of stem cells has emerged as a promising approach in the management of congenital heart disease.
• Preclinical studies have mostly focused on modeling right ventricle dysfunction or failure and pulmonary artery hypertension by using pressure or volume overload in vitro or in vivo.
• To date a limited number of clinical trials have assessed the efficacy of stem cell-based therapies in pediatric patients with congenital heart, mainly with hypoplastic left heart syndrome, exhibiting encouraging results.
What Are the Clinical Implications?
• Stem cell delivery to the diseased heart as an adjunct to surgical palliation may provide some benefits over surgery alone in terms of cardiac function, somatic growth, and quality of life.
• Any knowledge gained from the use of stem cells in adults should only be used as a guide and should not be arbitrarily extrapolated to the pediatric congenital heart disease population without adequate preclinical testing.
• In vivo molecular imaging, administration of immunosuppressive and prosurvival agents, and advances in tissue engineering are promising ways of boosting stem cell survival, retention, and regeneration and therefore improving future clinical outcomes.
with the PRISMA guidelines (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) ( Table I in the  online-only Data Supplement) . 21 Bibliographic search was performed in Medline (PubMed), ClinicalTrials.gov, and Cochrane Library-Cochrane Central Register of Controlled Trials (CENTRAL). The last search date was April 23, 2017. The following medical subject heading terms were used in combination with Boolean operators (AND, OR, NOT): congenital cardiac defect, congenital heart defect, congenital heart disease, congenital cardiac disease, heart abnormality, cardiac abnormality, heart malformation, cardiac malformation, stem cells, progenitor cells, mother cells, cardiosphere-derived cells, bone marrow-derived mononuclear cells. Two independent reviewers (DIT, KSM) screened all articles retrieved by the initial search. All disagreements were resolved with discussion, and final decision was reached by consensus with a third reviewer (EKO). Reference lists were systematically searched for relevant articles in a snowball procedure.
Our study is a systematic review of published papers and ongoing clinical trials. No direct patient contact or interventions took place at any stage of our research project. Primary patient data were not used either. Considering our study design, patient confidentiality or direct patient harm could not possibly occur; therefore, Institutional Review Board approval was not deemed necessary
Study Criteria
Ongoing and published preclinical and clinical studies reporting on the use of stem cells for the treatment of CHD were included in this systematic review. Excluded studies met ≥1 of the following criteria: (1) irrelevant to the subject studies, (2) studies published in a non-English language, (3) reviews and meta-analyses, and (4) editorials, perspectives, and letters to the editors. No sample size restriction was applied when screening for eligible studies.
Data Extraction and Tabulation
Detailed data extraction and tabulation were not attempted given the high heterogeneity in reporting of outcomes among eligible studies. Because no cumulative statistical analysis or meta-analysis was possible, the data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure. Ultimately, a purely descriptive presentation of available data was adopted.
Assessment of Study Quality and Publication Bias
The modified Jadad scale was used to assess the risk of bias of included randomized controlled trials (RCTs). Randomization, blinding, withdrawals/dropouts, inclusion/exclusion criteria, adverse effects, and statistical analysis were included in the modified Jadad scale. 22 This score ranges from 0 to 8,with a score of 4 to 8 denoting high quality and 0 to 3 suggesting low quality. The quality of included non-RCT studies was evaluated using the Newcastle-Ottawa Quality scale. 23 In the item assessing whether the follow-up period was long enough for outcomes to occur, the cutoff value was a priori set at 1 year after intervention, whereas regarding the item about the adequacy of follow-up, a 90% rate was also a priori adopted. Items pertaining to the comparability of groups were marked as not applicable in the noncomparative studies. Two reviewers (DIT and KSM) working independently rated the studies, and final decision was reached by consensus with a third reviewer (EKO).
RESULTS AND DISCUSSION

Characteristics of Eligible Studies
The initial literature search yielded 207 potentially relevant records. After screening titles and abstracts, 22 reports were retrieved for full-text evaluation. Overall, 15 studies satisfied predetermined search criteria, and 4 additional studies were identified through snowball search procedures. Ultimately, 19 studies were included in this systematic review [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] : 8 preclinical, 24-31 6 clinical, [32] [33] [34] [35] [36] [37] and 5 ongoing trials. [38] [39] [40] [41] [42] Figure displays the flow chart showing the process of study selection. Quality assessment of included RCTs using the modified Jadad scale can be reviewed in Table II in the online-only Data Supplement. The Newcastle-Ottawa rating scale results for all comparative and noncomparative non-RCT studies are summarized in Table III in the online-only Data Supplement.
Types of Stem Cells
Stem cell transplantation can be achieved through several routes of delivery to the heart, including intracoronary, intramyocardial, intravenous, and epicardial. It is important to note that preclinical studies seem to report mainly on intramyocardial 24, 26, 27, 31 or intravenous [28] [29] [30] routes, whereas clinical studies have primarily focused on the intracoronary route, 32, [34] [35] [36] [37] with only 1 case of intramyocardial transplantation. 33 Various types of stem cells have been used in adult and pediatric populations, [43] [44] [45] [46] [47] [48] with cardiac stem cells (CSCs) being the most prevalent in CHD so far. [34] [35] [36] Depending on their origin and the level of differentiation at which they are harvested, stem cells may exhibit different properties. In general, multipotent cells hold a strong regenerative capacity that allows them to generate all components of cardiac tissue, namely, endothelium, myocardium, epicardium, and stroma. CSCs derived from the mesenchymal component of heart tissue have been found to possess a multipotent ability. 49 It has been suggested that the neonatal heart may be the optimal source of CSCs. First, although CSCs are abundant in the neonatal period, they do progressively decrease over time. Second, stem cells in neonatal hearts seem to have a greater regenerative ability than those derived from their adult counterparts. 50 Table 1 describes the characteristics of stem cells that have been used in cardiovascular medicine to date.
34-36,43-47
Stem Cell Therapy for CHD
Preclinical Studies
Because of the heterogeneity and complexity of anatomic anomalies in CHD, developing an animal model that accurately resembles humans is in fact quite challenging. 51, 52 However, right ventricle (RV) dysfunction and cardiac failure because of pressure or volume overload is a key feature of most CHDs, including HLHS and Tetralogy of Fallot. Therefore, research has been directed toward reproducing these alterations of cardiac physiology in experimental models. [24] [25] [26] In this context, a pressure-overload right-heart model using pulmonary artery banding has been evaluated in rats, 24 sheep, 25 and pigs. 26 Different types of stem cells were injected in animal hearts, 
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namely, skeletal myoblasts 24 , cord blood stem cells, 25 and mesenchymal stem cells 26 either intramyocardially 24, 26 or epicardially 25 . All studies reported a significant improvement of RV function in the intervention groups compared with their respective control groups (Table 2) .
Furthermore, Yerebekan et al 27 investigated intramyocardial umbilical cord blood mononuclear cell (UCBMC) transplantation in a swine model of RV volume overload. The authors implanted a transannular patch and distorted the pulmonary valve in the RV outflow tract, thus creating pulmonary insufficiency and RV volume overload that mimics the hemodynamic properties after the correction of Tetralogy of Fallot. The authors concluded that the UCBMC-implanted group had enhanced RV diastolic function, which could be potentially attributed to the increased angiogenesis prompted by the aforementioned cells. 27 The long-term safety and feasibility of UCBMC transplantation was recently evaluated in piglets, thus supporting the testing of such cell therapies in clinical studies. 53 Hyperkinetic pulmonary arterial hypertension (PAH) may be developed in patients with CHD, mainly in those with continuous intracardiac left-to-right shunt, and may significantly contribute to the increased mortality rates in patients with Eisenmenger syndrome. 11 Cao et al 28 and Liu et al 29 both established a hyperkinetic PAH model using common carotid artery and jugular vein anastomosis in rabbits and rats, respectively. The first group used the transplantation of endothelial progenitor cells isolated from the bone marrow transfected with human hypoxia-inducible factor-1α. They noticed an attenuation of the shunt flow-induced PAH that could be explained by the increased density of pulmonary small arteries in the rabbits transplanted with human hypoxia-inducible factor-1α-transfected endothelial progenitor cells. 28 Similarly, Liu et al 29 used autologous adipose-derived stromal cells and suggested an amelioration of the PAH by means of the same angiogenic effect. A novel model of hemodynamic PAH using lung lobectomies was established in rats, and after transplantation of endothelial progenitor cells isolated from the bone marrow transfected with endothelial NO synthase, PAH was eventually reversed. 30 Finally, a research group recently demonstrated the safety and feasibility of intramyocardial administration of human mesodermal posterior 1-positive/stage specific embryonic antigen-1-positive cardiogenic mesodermal cells 4 months after a surgical procedure mimicking the repair of Tetralogy of Fallot. 31 In addition, benefits were noted regarding overloaded RV tissue remodeling and arrhythmic susceptibility that could be partially attributed to the significant decrease of perimyocyte fibrosis in the cell-treated group. However, no significant improvement was evident with regard to RV function. 31 
Clinical Studies
Although stem cell therapy has been associated with significant benefits in children with dilated cardiomyopathy, [54] [55] [56] [57] only a few studies have been published on children with CHD, and thus current experience is rather limited. Among various subtypes of CHD, HLHS has been at the forefront of efforts to improve cardiac func- [32] [33] [34] [35] [36] In 2010, Rupp et al 32 first described the intracoronary administration-through the dominant right coronary artery-of autologous bone marrow-derived progenitor cells (BMCs) in an 11-month critically ill infant with HLHS and persistent HF after a hybrid comprehensive stage II procedure. Three months after therapy, his clinical presentation was impressively improved with markedly reduced BNP levels and doubling of the LV ejection fraction (22% to 44%). 32 Another single case was recently reported by Burkhart et al, 33 who described the first intraoperative intramyocardial injection of autologous UCB stem cells in a 4-month infant undergoing a stage II palliation surgery. At the 3-month follow-up, the right ventricle (RV) ejection fraction had increased from 30% to 50%. However, whether this improvement was attributable to cell therapy, surgical palliation, or a combination of both was not clear. 33 The first prospective phase 1-controlled trial, named TICAP (Transcoronary Infusion of Cardiac Progenitor Cells), in a pediatric population with HLHS was published by Ishigami et al 34 in 2015. This trial was the largest endeavor to principally evaluate the safety and feasibility of autologous CDCs intracoronary delivery in 7 children 4 or 5 weeks after stage II or III palliative surgery. No serious adverse effects were noted, highlighting the safety of the procedure. Compared with baseline, cardiac function, evaluated by RV ejection fraction, significantly increased in the patients treated with CDC (46.9±4.6% to 54.0±2.8%, P<0.001) at 18-months follow-up, whereas no significant improvement was noted in the control group (46.7±4.4% at baseline versus 48.7±6.7% at 18 months, P=0.49). Compared with controls, the CDC-treated group also showed improved somatic growth (P<0.001) and reduced HF status (P=0.003). 34 These results persisted during the 36-month follow-up period. 35 Recently, the same research group published the PERSEUS randomized phase 2 controlled trial (Cardiac Progenitor Cell Infusion to Treat Univentricular Heart Disease), which was designed as 2 smaller studies. Patients were initially randomized to an intracoronary CDC-treated group after staged surgery and staged reconstruction alone (controls) (study A). 36 Furthermore, controls could receive CDC infusion on request 4 months after palliation (study B). 36 In study A, cardiac function was assessed after 3 months of the initial intervention, and patients treated with CDC 
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showed a significantly improved ventricular function compared with controls. The same effect was noted in study B for patients treated with CDC late at 3 months compared with baseline. Finally, at 1 year, patients treated with CDC from studies A (17 patients) and B (17 patients) showed improved ventricular function (P<0.001) and volumes (P<0.001), somatic growth (P<0.001), and quality of life along with a reduced HF status (P<0.001) and cardiac fibrosis (P=0.014) compared with baseline. 36 To date, this is the largest cohort study (n=34 patients) in this field that substantiates the safety profile and favorable long-term results of CDC intracoronary delivery in patients with HLHS. Because of their high-quality design and results, the TICAP and PERSEUS studies have collectively provided the strongest evidence to date.
Finally, Rupp et al 32 evaluated the intracoronary infusion of autologous BMMNCs in 9 severely ill children with HF, including 3 with CHD (1 double outlet right ventricle, 1 pulmonary atresia and ventricular septal defect, and 1 HLHS) and 6 with dilated cardiomyopathy. No unexpected adverse effects related to the procedure occurred. Also, 5 patients reported a decrease in New York Heart Association stage and BNP levels, suggesting that the application of autologous BMMNCs in congestive HF may be beneficial. 37 However, the quality of this study was mainly compromised by its noncontrolled nature and the inadequate follow-up of the patients with CHD. Table 3 summarizes all clinical studies published to date.
Tissue Engineering in Clinical Practice
Repair of CHD is generally considered among the most technically challenging surgical procedures. However, recent advances in pediatric heart surgery have contributed to increased survival rates relative to the past. 2, 3 To date, the main limitations in optimizing outcomes for patients with CHD after corrective surgery are the early obstruction of stents and the unmatched growth of prosthetic implants or grafts with the infant hearts, thus necessitating replacement. Tissue engineering may overcome these obstacles by creating scaffolds seeded with stem cells that have the potential to grow in parallel with cardiac and whole-body growth once implanted in the defective heart. 58 Although seeded scaffolds are currently a reality, only a few reports have verified this hypothesis so far. [58] [59] [60] [61] [62] The first report, published in 2001, referred to the transplantation of a tissue engineering-based vessel graft aiming at the reconstruction of a previously occluded pulmonary artery in a 4-year-old girl with single RV and pulmonary atresia. After 7 months, the transplanted vessel was completely patent with no evidence of aneurysm formation. 59 The same group reported the successful application of biodegradable tissue- *Refers to the number of patients who receive stem cell therapy for congenital heart disease, not the entire study sample.
engineered vascular autografts seeded with BMCs in 22 patients with CHD with no related stenosis or documented mortality. 60 Ultimately, the authors published the results of the application of tissue-engineered conduits and patches seeded with autologous MBCs in 23 and 19 patients, respectively. 58 Their results were impressive because no evidence of thrombosis, stenosis, or obstruction of the grafts after a median of 16.7 months was noted. Besides observed patency, diameter of the grafts also increased in size by 10% on average compared with the implanted size. 58 Encouraging results were also shown by Hibino et al, 61 who reported that the implantation of cavopulmonary conduits seeded with autologous BMMNCs in 25 patients with single-ventricle physiology. Although most patients had uneventful recovery and durable outcomes, 4 revealed graft stenosis and 1 partial mural thrombosis that were treated successfully with percutaneous angioplasty and administration of warfarin, respectively. 61 Finally, Cabanelas et al 62 implanted 4 endothelial progenitor cell-capturing stents, with no procedure-related complications, to maintain the patency of 2 modified Blalock-Taussig shunts and 1 ductus arteriosus in 3 children with cyanotic heart disease. Nevertheless, their success was limited by the partial occlusion of 2 stents after 5 and 5.5 months, which required balloon dilatation before elective definitive surgical correction. 62 Collectively, the advent of tissue engineering technology has shown encouraging results for the correction of CHD. Established protocols are currently under constant revision with the aim to regenerate constructs that will be as physiologically similar as possible to the native tissues or organs. Nevertheless, considering that no long-term studies exist, further research is warranted to draw definite conclusions.
Ongoing Trials
Five clinical trials are currently still recruiting patients (Table 4) . Among these trials, 3 are open-label phase 1 trials designed by the Mayo Clinic. [38] [39] [40] Particularly, NCT02549625 aims to address the safety and feasibility of intracoronary delivery of BMMNCs in patients with Fontan circulation and RV dysfunction.
38 NCT02914171 randomizes patients with Ebstein anomaly into 2 groups: those undergoing surgical intervention along with intramyocardial delivery of autologous BMMNCs (group A), and those undergoing surgery alone (group B). The primary end point is to assess the safety and feasibility 24 months after Ebstein repair. 39 Last, the same research group evaluates the intramyocardial delivery of autologous UCBMCs in patients with HLHS undergoing stage II palliation surgery focusing primarily on the safety of the procedure as well as the effects of UCBMCs on the RV function (NCT01883076). 40 Building on the TICAP and PERSEUS studies, which have undoubtedly attracted a lot of attention, [34] [35] [36] the same researchers are currently recruiting patients for a novel study called APOLLON (Cardiac Stem/Progenitor Cell Infusion in Univentricular Physiology). 41 This is a multicenter randomized phase 3 trial that will assess the efficacy of intracoronary injection of autologous CSCs in pediatric patients with HLHS undergoing stage II or III palliation surgery. Outcomes include the changes in EF (%), Ea/Ees (arterial elastance/ventricular elastance), ventricular stiffness, HF and quality of life index, as well as the number of adverse effects. 41 Finally, a phase 1 open label randomized controlled trial, named ELPIS (Allogeneic Human Mesenchymal Stem Cell Injection in Patients with Hypoplastic Left Heart Syndrome), aims to examine whether intramyocardial injection of allogeneic human mesenchymal stem cells in patients with HLHS undergoing bidirectional cavopulmonary anastomosis (group A) offers superior outcomes in terms of safety and changes in the RV function compared with those receiving intramyocardial placebo injection (group B). 42 Most clinical trials investigating the use of stem cellbased therapies in patients with CHD are exploratory and focus on feasibility and safety end points while also assessing changes in traditional markers of heart function, such as the ejection fraction (Table 4) . Secondary outcome measures pertaining to subtle changes in cardiogenesis and angiogenesis should also be included in the design of such clinical trials because these changes may actually precede a significant clinical improvement in the ejection fraction and may therefore allow an assessment of the efficacy of a given intervention at even earlier stages. In vivo molecular imaging is a promising and sensitive modality that may allow the integration of such outcome measures in clinical studies, 63, 64 independently of traditional echocardiography, which is known to suffer from high variability that may obscure the expected benefit. 65 Moreover, the rationale behind the selection of any particular cell type is not always clear and usually reflects the local expertise of the center and prior experimentation in preclinical models.
Challenges, Limitations, and Need for Well-Designed Clinical Trials
Despite preliminary encouraging results, considerable challenges still need to be overcome before stem cell therapy is considered a viable alternative or a useful adjunct to surgery for patients with CHD. Existing literature in this field is limited, and thus the design of appropriate clinical trials remains puzzling. The decision on the optimal stem cell type, route of administration, source of harvest (whether autologous or not), and potential interactions is primarily based on the previous experience in adults and the knowledge of their proper- ties from other in vivo and vitro experimental studies. In addition, because of the heterogeneous nature of CHD, the development of animal models that closely resemble the alterations in human cardiovascular physiology in such scenarios is technically challenging, and this poses difficulties in the acquisition of new knowledge. Finally, tissue engineering is currently in an infant stage, and the safety and durability of cell-based regenerated implants need to be validated before profoundly applying them in clinical practice.
Several lessons can be learned from previous studies assessing the efficacy and safety of stem cellregenerative therapies in adults with cardiovascular disease. It is important to note that none of the somatic stem cells used in clinical trials have been proven to differentiate in vivo into functional cardiomyocytes; it is accepted that the benefits are thought to be secondary to a paracrine effect that is mediated by cell therapy. 63, 65 In particular, the limited and inconsistent benefit that has been demonstrated in autologous bone marrow stem cell trials in adults to date 66 is usually attributed to poor cell retention and survival. 63 As a result, in vivo molecular imaging to determine cell fate and dose-response effects after transplantation, 63, 64 combined with the use of immunosuppressive and prosurvival agents, 67, 68 have been recently introduced as possible ways to boost cell retention and survival. Similarly, novel tissue engineering techniques enabling the production of injectable scaffolds that provide the optimal microenvironment for homing, retention. and growth of stem cells may offer additional help in overcoming these barriers. 69 However, such lessons from clinical studies in adults should be extrapolated with caution to younger patients with CHD. The use of embryonic stem cells/induced pluripotent stem cells rather than adult BMMNCs may raise substantial concerns for tumorigenicity, 70, 71 although induced pluripotent stem cells have been associated with a lower risk for an adverse immunogenic response. 72 Moreover, arrhythmogenicity remains another important safety concern that needs to be considered in the design of any stem cell intervention. 73 The optimal delivery route also needs to be determined separately for each CHD entity because past experience in adult stem cell trials has shown significant variability between centers and patients with acute myocardial infarction versus ischemic cardiomyopathy for the intracoronary versus transendocardial routes. 65 Finally, as shown in adult stem cell trials, ethical and economic barriers should also be taken into account to assess the cost-effectiveness and regulatory profile of such interventions. 65 These critical points should accounted for in the design of future stem cell trials for CHD, and they may help provide valuable feedback on how to ensure the efficacy and safety of these interventions in the pediatric population.
CONCLUSIONS
Stem cell therapy, in the form of either direct transplantation to the heart or cell-based tissue engineering, has emerged as a strategy with potential benefits for patients with CHDs. It seems that stem cell delivery to the diseased heart as an adjunct to surgical palliation may provide some benefits over surgery alone in terms of cardiac function, somatic growth, and quality of life. Given the limited number of relevant studies and the lack of longterm follow-up of children who have already received such therapies, further research is warranted to clearly define the role of this novel therapeutic approach in clinical practice. Until then, stem cell therapies should be considered only in the setting of well-designed clinical trials.
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